Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Inclusion Criteria:

Participants will qualify for inclusion into Cohort 1, 2, or 3 only if they meet all the following criteria.

1. Be a biological male at birth who is ≥ 21 years of age at the time of informedconsent.

2. Have undergone a 68Ga-PSMA-11 (Illuccix or Gozellix) PET/CT imaging evaluationwithin 60 days before enrolling in the study. (Prior imaging with alternateradioactive imaging agents are allowed, but enrollment imaging must be with 68Ga-PSMA-11(Illuccix or Gozellix).

3. Have histopathologically confirmed prostate adenocarcinoma.

4. Have a life expectancy of ≥ 6 months as determined by the investigator.

5. Participants intended for enrollment in Cohort 1: Patients who have been newlydiagnosed with prostate cancer and have not received any prior treatment forprostate cancer and have undergone a 68Ga-PSMA-11 PET/CT imaging evaluation toevaluate potential spread of the disease.

6. Participants intended for enrollment in Cohort 2: Patients who have receivedprevious treatment for prostate cancer and have and have undergone 68Ga-PSMA-11PET/CT imaging evaluation for suspected recurrence (demonstrated by elevated PSAlevels). Participants intended for enrollment in Cohort 3: Patients who havemetastatic prostate cancer and undergone a 68Ga-PSMA-11 PET/CT imaging evaluationfor the initiation of RLT.

7. Be willing and able to provide informed consent and comply with the protocolrequirements.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply. All participants must NOT:

1. Have any medical condition or other circumstances that, in the opinion of theInvestigator, compromises the safety of the participant, the ability of theparticipant to comply with protocol requirements, the ability of the participant tocomplete the study, or confound study outcomes by being unable to produce reliabledata over the course of the study.